<DOC>
	<DOCNO>NCT00489099</DOCNO>
	<brief_summary>A study evaluate safety , tolerability , immunogenicity recombinant hepatitis B vaccine manufacture use upgrade production process . The primary hypothesis test 1 month third dose vaccine following : 1 ) 3 lot process upgrade vaccine induce similar seroprotection rate hepatitis B surface antigen ( HBsAg ) , 2 ) combine lots process upgrade vaccine induce adequate seroprotection HBsAg , 3 ) process upgrade vaccine induce geometric mean antibody titer HBsAg non-inferior superior induce current process vaccine .</brief_summary>
	<brief_title>A Research Study Test Safety , Tolerability , Immunogenicity Recombinant Hepatitis B Vaccine Manufactured With Upgrade Production Process ( V232-054 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>In general good health Female participant negative pregnancy test prior vaccination Day 1 History Hepatitis B Infection vaccination Known suspect hypersensitivity component Recombivax HBâ„¢ vaccine ( e.g. , aluminum , yeast ) Administration hepatitis B immune globulin , serum immune globulin , bloodderived product within 3 month prior vaccination Day 1 Receipt inactivate virus vaccine within 14 day live virus vaccine within 30 day prior vaccination Day 1 Participation prior study use investigational drug vaccine prior 3 month Known suspected impairment immunologic function recent use immunomodulatory medication , exclude topical inhaled steroid Pregnant nursing woman woman plan become pregnant within study period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>